Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunotherapy of metastatic kidney cancer
Autore:
Pizza, G; De Vinci, C; Lo Conte, G; Maver, P; Dragoni, E; Aiello, E; Fornarola, V; Bergami, T; Busutti, L; Boriani, S; Palareti, A; Capanna, R;
Indirizzi:
S Orsola M Malpighi Hosp, Dept Urol, Operat Unit Urol, Bologna, Italy S Orsola M Malpighi Hosp Bologna Italy Operat Unit Urol, Bologna, Italy S Orsola M Malpighi Hosp, Dept Oncol, Operat Unit Radiotherapy, Bologna, Italy S Orsola M Malpighi Hosp Bologna Italy nit Radiotherapy, Bologna, Italy Maggiore Hosp, Operat Unit Orthoped, Bologna, Italy Maggiore Hosp Bologna Italy Hosp, Operat Unit Orthoped, Bologna, Italy Univ Bologna, Dept Comp Sci, Bologna, Italy Univ Bologna Bologna ItalyUniv Bologna, Dept Comp Sci, Bologna, Italy Reconstruct Surg Ctr, Div Orthopaed 2, Florence, Italy Reconstruct Surg Ctr Florence Italy r, Div Orthopaed 2, Florence, Italy
Titolo Testata:
INTERNATIONAL JOURNAL OF CANCER
fascicolo: 1, volume: 94, anno: 2001,
pagine: 109 - 120
SICI:
0020-7136(20011001)94:1<109:IOMKC>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-CELL-CARCINOMA; HIGH-DOSE INTERLEUKIN-2; LUNG-CANCER; INTRALYMPHATIC INTERLEUKIN-2; RANDOMIZED TRIAL; NATURAL-HISTORY; INTERFERON; THERAPY; SURVIVAL; ADJUVANT;
Keywords:
immunotherapy; IL-2; lymphokine-activated killer cells; metastasis; transfer factor; interferon; renal cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Pizza, G S Orsola M Malpighi Hosp, Dept Urol & Nephrol, Operat Unit Urol, Via P Palagi 9, I-40138 Bologna, Italy S Orsola M Malpighi Hosp Via P Palagi 9 Bologna Italy I-40138 ly
Citazione:
G. Pizza et al., "Immunotherapy of metastatic kidney cancer", INT J CANC, 94(1), 2001, pp. 109-120

Abstract

From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 x 10(6) LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11-69 months later. The overall median survival of treated patients (28 months) was3.5-fold higher than the median survival of historical controls (7.5 months), and a Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL-2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low-dose immunomodulatory treatments. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 04:09:12